In a significant development for those alleging health impacts from the widely used herbicide Roundup, Bayer has announced a proposed $7.25 billion settlement to resolve a substantial number of lawsuits. The agreement, revealed Tuesday, aims to address claims that exposure to Roundup caused non-Hodgkin lymphoma. This move comes as Bayer simultaneously prepares for a Supreme Court hearing in April, centered on whether federal law preempts state-level claims regarding the product’s labeling.
The proposed settlement seeks to mitigate the financial and legal risks associated with ongoing litigation. While Bayer maintains that Roundup’s active ingredient, glyphosate, is safe when used as directed, the company has acknowledged the mounting costs of defending against thousands of lawsuits. Bayer CEO Bill Anderson stated the settlement provides “a road to closure” for the company, which acquired Roundup manufacturer Monsanto in 2018. The outcome of the Supreme Court case, however, remains separate and will not be directly affected by this agreement.
The settlement, filed in St. Louis Circuit Court in Missouri, requires court approval. It is designed to cover current and future claims from individuals exposed to Roundup, potentially resolving the vast majority of the over 125,000 lawsuits filed since 2015. The agreement establishes a fund that will distribute payments over up to 21 years, with the total amount potentially reaching $7.25 billion, according to court documents.
Settlement Payouts Vary Based on Exposure and Diagnosis
The amount of compensation individual plaintiffs receive will depend on several factors, including their level of exposure to Roundup, age at diagnosis and the severity of their non-Hodgkin lymphoma. Those with extensive exposure, such as agricultural, industrial, or turf workers diagnosed with an aggressive form of the illness before age 60, could receive an average of $165,000. Residential users diagnosed between 60 and 77 with a less aggressive form of the disease are slated for an average of $20,000, while those diagnosed at age 78 or older would receive an average of $10,000.
Attorney Christopher Seeger, representing current claimants, emphasized that the settlement aims to provide “meaningful compensation” to both current and future patients. However, some legal representatives express skepticism about the adequacy of the proposed payouts. Attorney Matt Clement, representing approximately 280 plaintiffs, voiced surprise at the settlement terms and anticipates many of his clients will opt out, deeming the proposed amounts “exceedingly too small.”
Supreme Court Case and Regulatory Landscape
Bayer argues that the Environmental Protection Agency’s (EPA) approval of Roundup’s label, which does not include a cancer warning, should shield the company from state-level failure-to-warn lawsuits. The EPA has stated that glyphosate is not likely to be carcinogenic to humans when used as directed. Bayer is appealing a Missouri case to the Supreme Court, where a man who developed non-Hodgkin lymphoma after using Roundup on a community garden was awarded $1.25 million.
Notably, the Trump administration reversed the Biden administration’s position and sided with Bayer in this case, a move that drew criticism from some groups. Simultaneously, Bayer has been lobbying state legislatures to enact laws protecting pesticide manufacturers from state-level lawsuits when their products adhere to federal labeling requirements. North Dakota and Georgia have already passed such legislation, in April and May of last year, respectively. Stat News reported on this legislative effort.
Bayer has already ceased sales of glyphosate-based Roundup for residential lawn and garden use due to the litigation, but glyphosate remains a key component of agricultural products designed for use with genetically modified, herbicide-resistant crops. The company contends this approach allows farmers to increase yields while promoting soil conservation through reduced tilling.
The proposed settlement represents a significant step toward resolving a long-standing legal battle, but its ultimate success hinges on court approval and the willingness of plaintiffs to accept the terms. The Supreme Court’s upcoming decision will also play a crucial role in shaping the future of Roundup litigation and the regulatory landscape surrounding glyphosate-based herbicides.
Disclaimer: This article provides informational content only and should not be considered medical or legal advice. Please consult with qualified professionals for personalized guidance.
What are your thoughts on this settlement? Share your comments below, and please share this article with your network.
